Avillion LLP: US FDA accepts New Drug Application filed by A

Results from Phase III trials conducted by Avillion in over 4,000 patients show that PT027, a novel fixed-dose combination of albuterol and budesonide, significantly reduced the risk of a severe

Related Keywords

London , City Of , United Kingdom , United States , Canada , American , Allison Jeynes , George Underwood , Drug Administration , American Thoracic Society International Conference , Prnewswire Avillion , Astrazeneca , Global Asthma Network , International Conference , Blackstone Life Sciences , Global Initiative For Asthma , Most Recent National Asthma Data , American Thoracic Society , New Drug Application , New England Journal , Chief Executive Officer , Global Initiative , Clarus Ventures , Royalty Pharma , Thoracic Society International Conference , Global Asthma , Global Asthma Report , Recent National Asthma , Global Strategy , Asthma Management , Care Respir , Allergy Clin Immunol , World Allergy Organ , Prim Care Respir , Pavillion , Oaccepts , Drug , Application , Iled , T027 , Eeded , Treatment , Prevention , Symptoms , Asthma , Patients ,